Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2018
SIETES contiene 92427 citas

 
 
 1 a 18 de 18 
Presentar resultados
Seleccionar todas
2. Cita con resumen
Dickerson F, Adamos M, Katsafanas E, Khushalani S, Origoni A, Savage C, Schweinfurth L, Stallings C, Sweeney K, Goga J, Yolken RH. Adjunctive probiotic microorganisms to prevent rehospitalization in patients with acute mania: A randomized controlled trial . Bipolar Disorders 2018:25 de abril. [Ref.ID 102603]
3. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
5. Cita con resumen
Huizinga P, Kluytmans-van den Bergh M, van Rijen M, Willemsen I, van't Veer N, Kluytmans J. Proton pump inhibitor use is associated with extended-spectrum ß-lactamase-producing enterobacteriaceae rectal carriage at hospital admission: a cross-sectional study. Clin Infect Dis 2017;64:361-3. [Ref.ID 101508]
6. Cita con resumen
Huizinga P, Kluytmans– van den Bergh M, Willemsen I, van ‘t Veer N, Kluytmans J. Proton pump inhibitor use is associated with extended-spectrum ß-lactamase–producing Enterobacteriaceae rectal carriage at hospital admission: a cross-sectional study . Clin Infect Dis 2016;64:361-3. [Ref.ID 101382]
7.Tiene citas relacionadas Cita con resumen
Li B-Z, Threapleton DE, Wang JY, Xu J-M, Yuan J-Q, Zhang C, Li P, Ye Q-L, Guo B, Mao C, Ye DQ. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ 2015;351:h4052. [Ref.ID 99413]
8.Tiene citas relacionadas Cita con resumen
Braden B. The best and worst treatments for Helicobacter pylori. BMJ 2015;351:h4146. [Ref.ID 99411]
9. Cita con resumen
Anónimo. Antibiotics in infancy linked to childhood obesity. NPS MedicineWise 2014:23 de diciembre. [Ref.ID 98432]
11.Tiene citas relacionadas
Johnston BC, Goldenberg JZ, Guyatt GH. Probiotics for the prevention of Clostridium difficile - Associated diarrhea. Ann Intern Med 2013;158:706-7. [Ref.ID 95399]
12.Tiene citas relacionadas
Oscherwitz S. Probiotics for the prevention of Clostridium difficile - Associated diarrhea. Ann Intern Med 2013;158:706. [Ref.ID 95398]
13.Tiene citas relacionadas
Keller DL. Probiotics for the prevention of Clostridium difficile - Associated diarrhea. Ann Intern Med 2013;158:706. [Ref.ID 95397]
14.Tiene citas relacionadas Cita con resumen
Johnston BC, Ma SSY, Goldenberg JZ, Thorlund K, Vandvik PO, Loeb M, Guyatt GH. Probiotics for the prevention of Clostridium difficile - Associated diarreha: a systematic review and meta-analysis. Ann Intern Med 2012;157:878-88. [Ref.ID 94251]
15.Tiene citas relacionadas
Tack J. Antibiotic therapy for the irritable bowel syndrome. N Engl J Med 2011;364:81-2. [Ref.ID 90017]
16.Tiene citas relacionadas Cita con resumen
Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP, for the TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32. [Ref.ID 90014]
17. Cita con resumen
Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008;453:620. [Ref.ID 83572]
18. Cita con resumen
Guarner F, Malagelada J-R. Gut flora in health and disease. Lancet 2003;361:512-9. [Ref.ID 64967]
Seleccionar todas
 
 1 a 18 de 18